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Other names: IRF-1; MAR 
Location: 5q23.3 
Note: Interferon regulatory factor 1 belongs to a family 
of transcription factors described for their role in
regulating type I and type II interferons. Specifically, 
IRF1 has been identified as an activator of interferon 
alpha and beta transcription. Furthermore, it has been 
shown to play a role in the regulation of tumour 
suppression. IRF1 lies between interleukin (IL)-5 and 
CDC25C and is centromeric to IL-3 and GM-CSF. A 
number of mechanisms have been identified through 
which IRF1 is inactivated in various cancers. These, 
mechanisms include, deletion of the IRF1 region of 
chromosome 5q31; expression of IRF2; exon-skipping; 
binding of nucleophosmin; inactivation of tumour 
suppression by human papilloma viral oncogene, E7; 
and alternative splice variants lacking exons 7, 8, 9. 
DNA/RNA 
Description 
7.72 kb with 10 exons and 9 introns. 
Transcription 
2.035kb mRNA. Coding sequence: CDS 198-1175. 
IRF1 mRNA is expressed in low levels in a variety of 
tissues including, heart, lung, thymus, kidney and 
activated spleen. 
Protein 
Note: IRF1 protein consists of 325 aa (36 kDa). 
Description 
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Function 
Transcriptional activator of type I interferons. 
Mutations 
Note: Deletion in 5q rearrangement of IRF1 are 
associated with preleukemic myelodysplastic syndrome 
(MDS) and acute myelogenous leukemia (AML). The 
most commonly reported cytogenetic abnormalities in 
leukaemia and preleukaemic myelodysplastic 
syndromes are found within 5q or loss of the entire 
choromosome 5. The most commonly deleted region 
was found to be 5q31. Willman et al. reported the 
tumour suppressor gene, IRF1 is situated within this
5q31 region. A common translocation found in AML is 
between chromosome 8q22 and chromosome 21q22. 
This translocation is found in approximately 40% of 
FAB-M2 AML and 8-20% of all AML. 
Implicated in 
Acute myeloid leukaemia (AML) 
Disease 
AML is an heterogenous disease representating clonal 
haematopoietic stem cell disorders. Initially classified 
under a French-American-British (FAB) co-operative 
group describing eight categories dependent on cell 
morphology on May-Grunwald-Giemsa (MGG) 
staining of peripheral blood and bone marrow smears. 
More recently, the World Health Organisation (WHO) 
proposed a new classification dependent on 
morphological, cytochemical, immunophenotypic, 
cytogenetic and molecular determinants that 
incorporates more recent developments in this disease 
and thereby reduce the limitations experienced under 
the FAB classification. Activation of the mutant N-ras 
gene in some myeloid cell lines induced growth 
suppression through IRF1. 
Prognosis 
Prognosis is poor for most AML patients, depending o  
age and other unfavorable biological features. 
Cytogenetics 
Translocations: t(8;21)(q22;q22), inv(16)(p13q22), 




Note: 30% of patients exhibit a deletion in 
chromosome 5q. 
Disease 
MDS is an heterogenous group of diseases representing 
clonal bone marrow disorders. They are characterised 
by cytopenias with ineffective haematopoisis often 
progressing despite bone marrow transplants and may 
result in acute myeloid leukaemia. Chromosomal 
abnormalities are commonly found in this disease. 
Breast cancer 
Disease 
The transcriptional regulation of human caspase-8 gne 
expression in the breast tumour cell line, MCF-7 was 
studied and found to be induced by IFN-gamma 
inducible transcription factor IRF1. Further studies 
have shown that IRF1 behaves as a tumour suppressor 
gene in breast cancer through caspase activation and 
induction of apoptosis. This suppression of apoptosis 
was observed independently of p53. Pizzoferrato et al., 
showed that ectopic expression of IRF1 using an 
adenovirus delivery system led to a decrease in survivin 
expression and an increase in cell death in breast cancer 
cell lines. This study also showed that p21 was up-
regulated in IRF1-infected breast cancer cells 
independent of p53 modulation. Microarray analysis of 
clinically defined invasive breast carcinoma identified a 
negative correlation with IRF1 expression and tumour 
grade. High-grade breast carcinomas were found not to 
maintain IRF1 expression. IRF1 has also been shown t  
induce ligand-independent fas-associated death 
domain/caspase-8 mediated apoptosis in breast cancer 
cells. 
Cytogenetics 
A single nucleotide polymorphism, A4396G in IRF1 
was found to occur more frequently in breast cancer 
cell lines than in the general population. In addition, 
this polymorphism was more frequently expressed in 
the African American population than the European 
population. 
Cervical cancer 
Note: Alternative splicing of exons 7, 8 and 9 is 
implicated in cervical cancer. 
Disease 
Lee et al., demonstrated that p27Kip1 inhibits hTERT 
mRNA expression and telomerase activity through 
post-transcriptional up-regulation by IFN-gamma/IRF-
1 signalling. 
Gastric cancer 
Note: A point mutation in the second exon of the IRF1 
gene with a methionine substituted with leucine at 
codon 8 was identified. 
Disease 
Loss of heterozygosity at the IRF1 locus was found in 9 
cases of histologically differentiated gastric 
adenocarcinomas. A mis-sense mutation in the residual 
allele was found in one case. This mutation in IRF1 
was reported by Nozawa et al. to lead to reduced 
transcriptional activity but no change in its DNA-
binding activity was observed. The loss of functional 
IRF1 is a key factor in development human gastric 
cancer. 
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Oesophageal cancer 
Disease 
Oesophageal cancer is an aggressive tumour with two 
subtypes described, including: oesophageal squamous 
cell carcinoma (ESCC) and oesophageal 
adenocarcinoma. Following IFNgamma stimulation of 
three oesophageal cancer cell lines IRF1 was produced 
but did not lead to cell death. In contrast, adenoviral-
IRF1 (Ad-IRF1) infection of these cell lines induced 
high IRF1 production resulting in apoptosis. 
Furthermore, a murine model of oesophageal cancer 
injected with Ad-IRF1 moderately inhibited tumour 
growth but did not induce tumour regression. Analysis 
of primary samples of oesophageal squamous cell 
carcinoma revealed decreased IRF1 expression and 
increased IRF2 expression compared to adjacent 
normal oesophageal tissue. In addition, overexpression 
of IRF1 inhibited tumorigenicity of ESCC cells when 
injected in vivo in nude mice. 
Prognosis 
Ranked eighth most common malignancy and sixth 
most frequent cause of cancer worldwide. 
Cytogenetics 
The most frequent occurance is loss of heterozygosity 
either single or multiple loci on chromosome 5q. The 
smallest deletion is found at 5q31.1 the same position 
for the IRF1 gene. 
Ovarian cancer 
Disease 
Interferon gamma has been shown to inhibit 
proliferation of a number of ovarian cancer cell lines in 
vitro. This growth inhibition and apoptotic effect in
ovarian cancer cells was associated with a sustained 
increase in both IRF1 and p21. Kim et al., proposed a 
role for IRF1 in mediating IFNgamma-induced 
apoptosis through activation of caspase-1 gene 
expression in IFNgamma-sensitive ovarian cancer cells. 
IFNgamma was shown to induce IRF1 through the 
IFNgamma signalling pathway which in turn activated 
caspase-1. This was shown to lead to apoptosis of 
ovarian cancer cells, 2774 and PA-1, both sensitive to 
IFNgamma. 
Prognosis 
Early stage diagnosis of epithelial ovarian cancer one
can anticipate 90% survival. However, only 20-30% of 
patients with stage III epithelial ovarian carcinoma 
survive after 5 years. 
Melanoma 
Disease 
Lowney et al., described evidence showing IRF1 
protein expression correlated to morphologic 




Bladder cancer is ranked 9th in worldwide cancer 
incidence. A recent study determined that tumour 
necrosis factor-related apoptosis-inducing ligand 
(TRAIL) expression and downstream TRAIL-regulated 
apoptotic mechanisms are involved in IFNalpha-
induced cell death in human bladder cancer cell line
through a STAT1 /IRF1-dependent pathway. 
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